Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic factors affecting β-blocker metabolism and response.

Expert opinion on drug metabolism & toxicology - 1 Oct 2020

Thomas Cameron D, Johnson Julie A

Abstract excerpt

INTRODUCTION: β-blockers are among the most widely prescribed of all drugs, used for treatment of a large number of cardiovascular diseases. Herein we evaluate literature pertaining to pharmacogenetics of β-blocker therapy, provide insight into the robustness of the genetic associations, and determine the appropriateness for translating these genetic associations into clinical practice. AREAS COVERED: A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Cardiac electrophysiology and arrhythmias

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Genotype

Share to Heart Failure Treatment and Management

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Receptors, Adrenergic, beta-1

Source

Open in PubMed Open full text

Identifiers

PMID: 32726152
DOI: 10.1080/17425255.2020.1803279
PMCID: PMC7606773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic factors affecting β-blocker metabolism and response.PMID 32726152Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.Semantic proximity Read ↗

Pharmacogenetic polymorphisms affecting bisoprolol response.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.Semantic proximity Read ↗

Cardiovascular pharmacogenomics.Semantic proximity Read ↗

Genetic variation, β-blockers, and perioperative myocardial infarction.Semantic proximity Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

Genetic determinants of response to cardiovascular drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.